FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Heinz Zwierzina

Research Profile

Disorders

Chemicals & Drugs

Procedures

Physiology

Anatomy

Tumor Cells, Cultured

Co-author Network

Publications

TOP 3
Frédéric Baron; Sergio Amadori; Michel Delforge; Claudio Denzlinger; Karel Indrak; Petra Muus; Gert Ossenkoppele; Dominik Selleslag; Stefan Suciu; Antoine Thyss; Heinz Zwierzina; Theo de Witte
Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group.
Heinz Zwierzina; Patrick Schöffski; Klaus Witthohn; Steinar Aamdal; Lothar Bergmann; Heiner Fiebig; Hans Lentzen
The preclinical and clinical activity of aviscumine: a potential anticancer drug.
Jack Cuzick; Andrea Decensi; Banu Arun; Powel H Brown; Monica Castiglione; Barbara Dunn; John F Forbes; Agnes Glaus; Anthony Howell; Gunter von Minckwitz; Victor Vogel; Heinz Zwierzina
Preventive therapy for breast cancer: a consensus statement.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Heinz Zwierzina (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Frédéric Baron; Sergio Amadori; Michel Delforge; Claudio Denzlinger; Karel Indrak; Petra Muus; Gert Ossenkoppele; Dominik Selleslag; Stefan Suciu; Antoine Thyss; Heinz Zwierzina; Theo de Witte
Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group.
Haematologica 2012;97(4):529-33.
2011: Heinz Zwierzina; Patrick Schöffski; Klaus Witthohn; Steinar Aamdal; Lothar Bergmann; Heiner Fiebig; Hans Lentzen
The preclinical and clinical activity of aviscumine: a potential anticancer drug.
European journal of cancer (Oxford, England : 1990) 2011;47(10):1450-7.
2011: Jack Cuzick; Andrea Decensi; Banu Arun; Powel H Brown; Monica Castiglione; Barbara Dunn; John F Forbes; Agnes Glaus; Anthony Howell; Gunter von Minckwitz; Victor Vogel; Heinz Zwierzina
Preventive therapy for breast cancer: a consensus statement.
The lancet oncology 2011;12(5):496-503.
2011: Judith Loeffler-Ragg; U Germing; Wolfgang R Sperr; H Herrmann; Heinz Zwierzina; Peter Valent; Hanno Ulmer; Reinhard Stauder
Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes.
Critical reviews in oncology/hematology 2011;78(2):150-61.
2010: Heinz Zwierzina; Alberto Bardelli; Fortunato Ciardiello; Manuela Gariboldi; Leif Håkansson; Diether Lambrechts; Guro E Lind; Judith Loeffler-Ragg; Hans Schmoll; Salvatore Siena; Josep Tabernero; Eric Van Cutsem
Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials.
Current opinion in molecular therapeutics 2010;12(6):703-11.
2010: Lothar Bergmann; B Berns; A G Dalgleish; Mikael von Euler; T T Hecht; G L Lappin; N Reed; S Palmeri; J Smyth; S Embacher-Aichorn; Heinz Zwierzina
Investigator-initiated trials of targeted oncology agents: why independent research is at risk?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(8):1573-8.
2009: Judith Loeffler-Ragg; Doris Mueller; Gabriele Gamerith; Thomas Auer; Sergej Skvortsov; Bettina Sarg; Ira Skvortsova; Klaus J Schmitz; Hans-Jörg Martin; Jens Krugmann; Hakan Alakus; Edmund Maser; Jürgen Menzel; Wolfgang Hilbe; Herbert Lindner; Kurt W Schmid; Heinz Zwierzina
Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib.
Molecular cancer therapeutics 2009;8(7):1995-2006.
2008: Judith Loeffler-Ragg; Ilona Schwentner; Georg M Sprinzl; Heinz Zwierzina
EGFR inhibition as a therapy for head and neck squamous cell carcinoma.
Expert opinion on investigational drugs 2008;17(10):1517-31.
2008: Heinz Zwierzina
Combining immunotherapy with classical anticancer therapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19 Suppl 7():vii252-5.
2008: Ilona Schwentner; Martina Witsch-Baumgartner; Georg M Sprinzl; Jens Krugmann; Alexandar Tzankov; Siegfried Jank; Heinz Zwierzina; Judith Loeffler-Ragg
Identification of the rare EGFR mutation p.G796S as somatic and germline mutation in white patients with squamous cell carcinoma of the head and neck.
Head & neck 2008;30(8):1040-4.
2008: Heinz Zwierzina
Biomarkers in drug development.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19 Suppl 5():v33-7.
2008: Sergej Skvortsov; Bettina Sarg; Herbert Lindner; Peter Lukas; Wolfgang Hilbe; Heinz Zwierzina; Ira Skvortsova
Cetuximab inhibits thymidylate synthase in colorectal cells expressing epidermal growth factor receptor.
Proteomics. Clinical applications 2008;2(6):908-14.
2007: Sergej Skvortsov; Ira Skvortsova; Taras Stasyk; Natalia Schiefermeier; Andreas Neher; Andreas R Gunkel; Günther K Bonn; Lukas A Huber; Peter Lukas; Christopher M Pleiman; Heinz Zwierzina
Antitumor activity of CTFB, a novel anticancer agent, is associated with the down-regulation of nuclear factor-kappaB expression and proteasome activation in head and neck squamous carcinoma cell lines.
Molecular cancer therapeutics 2007;6(6):1898-908.
2007: Taras Stasyk; Natalia Schiefermeier; Sergej Skvortsov; Heinz Zwierzina; Johan Peränen; Günther K Bonn; Lukas A Huber
Identification of endosomal epidermal growth factor receptor signaling targets by functional organelle proteomics.
Molecular & cellular proteomics : MCP 2007;6(5):908-22.
2006: Judith Loeffler-Ragg; Michael Steurer; H Ulmer; Sergej Skvortsov; B Kircher; Manfred Herold; Heinz Zwierzina; Reinhard Stauder
Elevated levels of serum CD44 and E-cadherin predict an unfavourable outcome in myelodysplastic syndromes.
Leukemia 2006;20(11):2064-7.
2006: Ira Skvortsova; Sergej Skvortsov; Bela-Andre Popper; Alfred Haidenberger; Maria Saurer; Andreas R Gunkel; Heinz Zwierzina; Peter Lukas
Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and - independent mechanisms.
Journal of radiation research 2006;47(2):183-96.
2006: Judith Loeffler-Ragg; Martina Witsch-Baumgartner; Alexandar Tzankov; Wolfgang Hilbe; Ilona Schwentner; Georg M Sprinzl; Gerd Utermann; Heinz Zwierzina
Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma.
European journal of cancer (Oxford, England : 1990) 2006;42(1):109-11.
2005: Heinz Zwierzina; Stefan Suciu; Judith Loeffler-Ragg; R Neuwirtova; P Fenaux; M Beksac; Jean-Luc Harousseau; Volkmar Nuessler; J Cermak; G Solbu; Rein Willemze; Theo de Witte; Sergio Amadori
Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group.
Leukemia 2005;19(11):1929-33.
2005: Heinz Zwierzina; Markus Borner
[Clinical development of targeted moledular cancer drugs].
Onkologie 2005;28 Suppl 4():35-9.
2005: Sergej Skvortsov; Ira Skvortsova; Bettina Sarg; Judith Loeffler-Ragg; Herbert Lindner; Peter Lukas; Josep Tabernero; Heinz Zwierzina
Irreversible pan-ErbB tyrosine kinase inhibitor CI-1033 induces caspase-independent apoptosis in colorectal cancer DiFi cell line.
Apoptosis : an international journal on programmed cell death 2005;10(5):1175-86.
2005: Judith Loeffler-Ragg; Sergej Skvortsov; Bettina Sarg; Ira Skvortsova; Martina Witsch-Baumgartner; Doris Mueller; Herbert Lindner; Heinz Zwierzina
Gefitinib-responsive EGFR-positive colorectal cancers have different proteome profiles from non-responsive cell lines.
European journal of cancer (Oxford, England : 1990) 2005;41(15):2338-46.
2005: Ira Skvortsova; Bela-Andre Popper; Sergej Skvortsov; Maria Saurer; Thomas Auer; Robert Moser; Hans Kamleitner; Heinz Zwierzina; Peter Lukas
Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells.
Journal of radiation research 2005;46(2):241-8.
2005: Gordon C Jayson; Clive Mulatero; Malcolm Ranson; Jamal Zweit; Alan Jackson; Lynn Broughton; John Wagstaff; Leif Hakansson; Gerard Groenewegen; J A L Lawrance; Meina Tang; Linda Wauk; Dan Levitt; Sandrine Marreaud; Frederic F Lehmann; Manfred Herold; Heinz Zwierzina
Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer.
European journal of cancer (Oxford, England : 1990) 2005;41(4):555-63.
2004: Sergej Skvortsov; Bettina Sarg; Judith Loeffler-Ragg; Ira Skvortsova; Herbert Lindner; Helmut Werner Ott; Peter Lukas; Karl Illmensee; Heinz Zwierzina
Different proteome pattern of epidermal growth factor receptor-positive colorectal cancer cell lines that are responsive and nonresponsive to C225 antibody treatment.
Molecular cancer therapeutics 2004;3(12):1551-8.
2004: Patrick Schöffski; S Riggert; Pierre Fumoleau; Mario Campone; Oliver Bolte; Sandrine Marreaud; Denis Lacombe; B Baron; Manfred Herold; Heinz Zwierzina; Karin Wilhelm-Ogunbiyi; H Lentzen; Chris Twelves
Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(12):1816-24.
2002: Giuseppe Giaccone; Cornelis J A Punt; Yoshitaka Ando; Rita Ruijter; Nobusuke Nishi; Marlies Peters; B Mary E von Blomberg; Rik J Scheper; Hans J J van der Vliet; Alfons J M van den Eertwegh; Marja Roelvink; Jos Beijnen; Heinz Zwierzina; HERBERT PINEDO
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(12):3702-9.
2002: Andreas M Kaufmann; Peter L Stern; Elaine M Rankin; Harald Sommer; Volkmar Nuessler; Achim Schneider; Malcom Adams; Toli S Onon; Thomas Bauknecht; Uwe Wagner; Karlijn Kroon; Julian Hickling; Christopher M Boswell; Simon N Stacey; Henry C Kitchener; Jennifer Gillard; Jantien Wanders; John St Clair Roberts; Heinz Zwierzina
Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(12):3676-85.
2002: Odile Cohen-Haguenauer; Felicia Rosenthal; Bernd Gänsbacher; Reinder L H Bolhuis; Karoline Dorsch-Häsler; Zelig Eshhar; Gösta Gahrton; Peter Hokland; Cecilia Melani; Elaine Rankin; Kris Thielemans; Richard Vile; Heinz Zwierzina; Klaus Cichutek
Opinion paper on the current status of the regulation of gene therapy in Europe.
Human gene therapy 2002;13(17):2085-110.
2002: Gordon C Jayson; Jamal Zweit; Alan Jackson; Clive Mulatero; Peter Julyan; Malcolm Ranson; Lynn Broughton; John Wagstaff; Leif Hakannson; Gerard Groenewegen; John Bailey; Nigel Smith; David Hastings; J A L Lawrance; Hamied A Haroon; Tim Ward; Alan T McGown; Meina Tang; Dan Levitt; Sandrine Marreaud; Frederic F Lehmann; Manfred Herold; Heinz Zwierzina
Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies.
Journal of the National Cancer Institute 2002;94(19):1484-93.
2002: D Lacombe; P Fumoleau; Heinz Zwierzina; Chris Twelves; L Hakansson; G Jayson; F Lehmann; J Verweij
The EORTC and drug development. European Organisation for Research and Treatment of Cancer.
European journal of cancer (Oxford, England : 1990) 2002;38 Suppl 4():S19-23.
2002: B Brunner; Eberhard Gunsilius; Petra Schumacher; Heinz Zwierzina; Guenther Gastl; Reinhard Stauder
Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia.
Journal of hematotherapy & stem cell research 2002;11(1):119-25.
2002: Johannes Fürst; Thomas Haller; Sabine Chwatal; Ewald Wöll; Peter C Dartsch; Martin Gschwentner; Anton Dienstl; Heinz Zwierzina; Florian Lang; Markus Paulmichl; Markus Ritter
Simvastatin inhibits malignant transformation following expression of the Ha-ras oncogene in NIH 3T3 fibroblasts.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2002;12(1):19-30.
2001: Theo de Witte; Stefan Suciu; Gregor Verhoef; Boris Labar; Eric Archimbaud; C Aul; Dominik Selleslag; A Ferrant; Pierre W Wijermans; Franco Mandelli; Sergio Amadori; Ulrich Jehn; Petra Muus; M Boogaerts; Robert Zittoun; Alois Gratwohl; Heinz Zwierzina; Anne Hagemeijer; Rein Willemze
Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS.
Blood 2001;98(8):2326-31.
2000: I Rollinger-Holzinger; B Eibl; Marc Pauly; U Griesser; F Hentges; Bernhard Auer; G Pall; Peter Schratzberger; Dietger Niederwieser; E H Weiss; Heinz Zwierzina
LST1: a gene with extensive alternative splicing and immunomodulatory function.
Journal of immunology (Baltimore, Md. : 1950) 2000;164(6):3169-76.
1999: Heinz Zwierzina; J E Anderson; I Rollinger-Holzinger; B Torok-Storb; Volkmar Nuessler; S D Lyman
Endogenous FLT-3 ligand serum levels are associated with disease stage in patients with myelodysplastic syndromes.
Leukemia 1999;13(4):553-7.
1998: V Nüssler; R Pelka-Fleisc; Frank Gieseler; Max Hasmann; Roland Löser; E Gullis; O Stötzer; Heinz Zwierzina; W Wilmanns
In vitro efficacy of known P-glycoprotein modulators compared to droloxifene E and Z: studies on a human T-cell leukemia cell line and their resistant variants.
Leukemia & lymphoma 1998;31(5-6):589-97.
1998: I Rollinger-Holzinger; U Griesser; V Pollak; Heinz Zwierzina
Expression and regulation of the thrombopoietin receptor variants MPLP and MPLK in PBMC.
Cytokine 1998;10(10):795-802.
1998: Markus Ritter; Peter Schratzberger; Heidi Rossmann; Ewald Wöll; K Seiler; Ursula Seidler; Norbert Reinisch; Christian M Kähler; Heinz Zwierzina; HJ Lang; Florian Lang; Markus Paulmichl; Christian Wiedermann
Effect of inhibitors of Na+/H+-exchange and gastric H+/K+ ATPase on cell volume, intracellular pH and migration of human polymorphonuclear leucocytes.
British journal of pharmacology 1998;124(4):627-38.
1998: Heinz Zwierzina; I Rollinger-Holzinger; Volkmar Nuessler; M Herold; Y G Meng
Endogenous serum thrombopoietin concentrations in patients with myelodysplastic syndromes.
Leukemia 1998;12(1):59-64.
1997: Volkmar Nuessler; Frank Gieseler; E Gullis; Renate Pelka-Fleischer; O Stötzer; Heinz Zwierzina; W Wilmanns
Functional P-gp expression in multiple myeloma patients at primary diagnosis and relapse or progressive disease.
Leukemia 1997;11 Suppl 5():S10-4.
1997: Alexandra J Croockewit; M H Bronchud; M S Aapro; M J Bargetzi; J Crown; A Gratwohl; W Lange; H Ludwig; G Martinelli; R Mertelsmann; Volkmar Nuessler; Rein Willemze; Theo de Witte; Robert Zittoun; Heinz Zwierzina
A European perspective on haematopoietic growth factors in haemato-oncology: report of an expert meeting of the EORTC.
European journal of cancer (Oxford, England : 1990) 1997;33(11):1732-46.
1997: Markus Ritter; Peter C Dartsch; Siegfried Waldegger; Thomas Haller; Heinz Zwierzina; HJ Lang; Florian Lang
Effects of bradykinin on NIH 3T3 fibroblasts pretreated with lithium. Mimicking events of Ha-ras oncogene expression.
Biochimica et biophysica acta 1997;1358(1):23-30.
1997: Volkmar Nuessler; E Gullis; Renate Pelka-Fleischer; F del Valle; H Diem; S Beyerlein; Heinz Zwierzina; W Wilmanns
Expression and functional activity of P-glycoprotein in adult acute myelogenous leukemia patients.
Annals of hematology 1997;75(1-2):17-26.
1997: Volkmar Nuessler; Renate Pelka-Fleischer; Heinz Zwierzina; W Wilmanns; Claudio Denzlinger
Effects of progesterone and leukotriene receptor antagonists in experimental models of P-glycoprotein-related resistance.
European journal of medical research 1997;2(4):159-64.
1997: A Grassegger; I Rollinger-Holzinger; Bernhard W H Zelger; Kurt Heim; Heinz Zwierzina; Peter Fritsch; Reinhard Höpfl
Spontaneous or interferon-gamma-induced T-cell infiltration, HLA-DR and ICAM-1 expression in genitoanal warts are associated with TH1 or mixed TH1/TH2 cytokine mRNA expression profiles.
Archives of dermatological research 1997;289(5):243-50.
1997: Markus Ritter; Ewald Wöll; Thomas Haller; Peter C Dartsch; Heinz Zwierzina; Florian Lang
Activation of Na+/H(+)-exchanger by transforming Ha-ras requires stimulated cellular calcium influx and is associated with rearrangement of the actin cytoskeleton.
European journal of cell biology 1997;72(3):222-8.
1997: V Nüssler; Frank Gieseler; Heinz Zwierzina; E Gullis; Renate Pelka-Fleischer; H Diem; W Abenhardt; R Schmitt; I Langenmayer; A Wohlrab; Hans-Jochem Kolb; W Wilmanns
Idarubicin monotherapy in multiply pretreated leukemia patients: response in relation to P-glycoprotein expression.
Annals of hematology 1997;74(2):57-64.
1996: Christian Marth; Alain G Zeimet; M Herold; C Brumm; Gudrun Windbichler; Elisabeth Müller-Holzner; Felix Offner; H Feichtinger; Heinz Zwierzina; Guenter Daxenbichler
Different effects of interferons, interleukin-1beta and tumor necrosis factor-alpha in normal (OSE) and malignant human ovarian epithelial cells.
International journal of cancer. Journal international du cancer 1996;67(6):826-30.
1996: V Nüssler; Renate Pelka-Fleischer; Heinz Zwierzina; C Nerl; B Beckert; Frank Gieseler; H Diem; G Ledderose; E Gullis; H Sauer; W Wilmanns
P-glycoprotein expression in patients with acute leukemia-clinical relevance.
Leukemia 1996;10 Suppl 3():S23-S31.
1996: Heinz Zwierzina; T Bammer; I Rollinger-Holzinger; M Herold; P Fenaux; V Nüssler; E Hoflehner; D Geissler
In vitro stimulation of erythropoiesis by stem cell factor alone in myelodysplastic syndrome patients with elevated endogenous erythropoietin serum levels.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(6):1031-8.
1996: HH Gerhartz; Heinz Zwierzina; J Walther; P Fenaux; M Hayat; A Jacobs; A V Hoffbrand; M Dardenne; G Solbu; Stefan Suciu
Interleukin-3 plus low-dose cytosine arabinoside for advanced myelodysplasia: a pilot study. EORTC Leukemia Group.
Cancer investigation 1996;14(4):299-306.
1995: Felix Offner; Peter Obrist; Sylvia Stadlmann; H Feichtinger; Paul Klingler; M Herold; Heinz Zwierzina; Anton Hittmair; Gregor Mikuz; B Abendstein
IL-6 secretion by human peritoneal mesothelial and ovarian cancer cells.
Cytokine 1995;7(6):542-7.
1995: I Holzinger; A de Baey; Gerald Messer; Gerold Kick; Heinz Zwierzina; Elisabeth H Weiss
Cloning and genomic characterization of LST1: a new gene in the human TNF region.
Immunogenetics 1995;42(5):315-22.
1994: HH Gerhartz; R Marcus; Alain Delmer; Heinz Zwierzina; Stefan Suciu; M Dardenne; G Solbu; T de Witte; A Jacobs; G Visani
A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.
Leukemia 1994;8(1):16-23.
1994: G Jakob; Johannes Mair; K P Vorderwinkler; G Judmaier; P König; Heinz Zwierzina; M Pichler; Bernd Puschendorf
Clinical significance of urinary cyclic guanosine monophosphate in diagnosis of heart failure.
Clinical chemistry 1994;40(1):96-100.
1994: V Nüssler; Renate Pelka-Fleischer; Heinz Zwierzina; C Nerl; B Beckert; E Gullis; Frank Gieseler; S Bock; R Bartl; Petro E Petrides
Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndromes--first experience with their reversal.
Annals of hematology 1994;69 Suppl 1():S25-9.
1993: Heinz Zwierzina
Practical aspects of cytokine therapy.
Stem cells (Dayton, Ohio) 1993;11(3):144-53.
1993: D Soucek; Gerhard Ransmayr; Klaus Twerdy; Heinz Zwierzina; richard greil; E Fritsch; H Maier; A Pallua; F Gerstenbrand
Extensive meningeal involvement as the primary manifestation of a systemic small lymphocytic lymphoma: favourable outcome after neuraxial irradiation without chemotherapy.
British journal of haematology 1993;83(4):674-5.
1993: Heinz Zwierzina; I Holzinger; S Gaggl; H Wolf; S Schöllenberger; C Lam; T Bammer; D Geissler; I Lindley
Recombinant human interleukin-8 restores function in neutrophils from patients with myelodysplastic syndromes without stimulating myeloid progenitor cells.
Scandinavian journal of immunology 1993;37(3):322-8.
1992: Heinz Zwierzina; S Schöllenberger; M Herold; F Schmalzl; J Besemer
Endogenous serum levels and surface receptor expression of GM-CSF and IL-3 in patients with myelodysplastic syndromes.
Leukemia research 1992;16(12):1181-6.
1992: C Barnas; Heinz Zwierzina; Martina Hummer; Barbara Sperner-Unterweger; A Stern; W Wolfgang Fleischhacker
Granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment of clozapine-induced agranulocytosis: a case report.
The Journal of clinical psychiatry 1992;53(7):245-7.
1992: M Herold; F Schmalzl; Heinz Zwierzina
Increased serum interleukin 6 levels in patients with myelodysplastic syndromes.
Leukemia research 1992;16(6-7):585-8.
1992: Rein Willemze; N van der Lely; Heinz Zwierzina; Stefan Suciu; G Solbu; HH Gerhartz; Boris Labar; G Visani; M E Peetermans; A Jacobs
A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. EORTC Leukemia Cooperative Group.
Annals of hematology 1992;64(4):173-80.
1992: HH Gerhartz; R Marcus; Alain Delmer; Heinz Zwierzina; T de Witte; A Jacobs; G Visiani; D Fiere; Pieter Sonneveld; B Labar
Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia Group.
Infection 1992;20 Suppl 2():S116-23.
1991: Heinz Zwierzina; M Herold; S Schöllenberger; D Geissler; F Schmalzl
Detection of soluble IL-2 receptor in the serum of patients with myelodysplastic syndromes: induction under therapy with GM-CSF.
British journal of haematology 1991;79(3):438-43.
1991: Heinz Zwierzina; M Herold; D Geissler; S Schöllenberger; F Schmalzl
Soluble interleukin-2 (IL-2) receptor expression in patients with myelodysplastic syndromes is induced by granulocyte-macrophage colony-stimulating factor and IL-3.
Blood 1991;77(12):2795-6.
1991: Norbert Sepp; Heinz Zwierzina; J Smolle; F Schmalzl; Peter Fritsch; Gerold Schuler
Epidermal Langerhans cells in myelodysplastic syndromes are abnormal.
The Journal of investigative dermatology 1991;96(6):932-6.
1991: Heinz Zwierzina; G J Mufti; F Schmalzl
Therapy of myelodysplastic syndromes: advances and perspectives. Innsbruck, Austria, October 7-10, 1990.
Leukemia 1991;5(2):166-85.
1991: Heinz Zwierzina; S Hoffmann; F Schmalzl; H Braunsteiner
[Hematopoietic growth factors].
Wiener medizinische Wochenschrift (1946) 1991;141(14):311-20.
1991: Heinz Zwierzina; F Schmalzl; H Braunsteiner
[In vitro effects and possible clinical relevance of interleukin 3].
Acta medica Austriaca 1991;18(1):24-7.
1990: David Nachbaur; H Denz; Heinz Zwierzina; F Schmalzl; H Huber
Stimulation of colony formation of various human carcinoma cell lines by rhGM-CSF and rhIL-3.
Cancer letters 1990;50(3):197-201.
1989: HH Gerhartz; G Visani; Alain Delmer; Heinz Zwierzina; M Ribeiro; A Jacobs; R Marcus; M Baumelou; D Fière; Boris Labar
Low-dose Ara-C plus granulocyte/macrophage colony-stimulating factor for the treatment of myelodysplastic syndromes. EORTC Leukemia Group.
Bone marrow transplantation 1989;4 Suppl 3():36-7.
1989: D Geissler; Heinz Zwierzina; Christoph Pechlaner; S Gaggl; F Schmalzl; Günther Konwalinka; H Braunsteiner
Abnormal megakaryopoiesis in patients with myelodysplastic syndromes: analysis of cellular and humoral defects.
British journal of haematology 1989;73(1):29-35.
1989: Heinz Zwierzina; Norbert Sepp; E Ringler; F Schmalzl
Delayed maturation of skin window macrophages in myelodysplastic syndromes.
Leukemia research 1989;13(6):433-5.